Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker
September 20, 2024Your subscription includes
Unlimited Access to All Content from
The Los Angeles Post
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker
September 20, 2024Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive
September 02, 2024Roche on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye
July 25, 2024Shares in SAP rose as much as 7% to reach an all-time high on Tuesday after Europe's largest software maker reported better-than-expected quarterly operating
July 23, 2024Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure
July 18, 2024Serbia will give Mercedes-Benz, Volkswagen and Stellantis the opportunity to purchase lithium for car batteries as the nation prioritises European over Chinese
July 18, 2024Bayer said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth
July 17, 2024Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight
December 04, 2023Shares of Pfizer and German partner BioNTech fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some
April 26, 2024Bayer beat first-quarter analyst forecasts as it reported a slight drop in adjusted earnings on Tuesday, providing a respite for the CEO's turnaround efforts.
May 29, 2024Germany's Bayer has aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy, dealing a fresh blow to the embattled drugmaker and throwing
November 20, 2023